World Immunotherapy Congress 2017 Basel, Switzerland 31 October - 2 November, 2017

Description:
Immunotherapy currently offers the brightest hope for cancer treatment. New developments with checkpoint inhibitors and co-stimulatory targets have enabled some stunning breakthroughs and high optimism for the sector. Recently, there have been some incredibly exciting new therapies in areas such as CAR-T and Oncolytic Viral Immunotherapy.

Our vision is to bring together the full community and provide a single meeting point for the whole value chain. It is where science meets business to make immunotherapy the cornerstone of the fight against cancer.

After a first successful edition, the World Immunotherapy Congress will once again bring leading clinicians, pharmaceutical companies, biotechs and research institutes together, and will take place alongside the flagship European Antibody Congress, as well as the World Biosimilar Congress and the World HPAPI Congress.

Prices:
Final standard price: EUR 3160
Final academic price: EUR 1580

Speakers:Roy Baynes, SVP and Head, Global Clinical Development, Chief Medical Officer, MSD / Puja Sapra, Executive Director, Pfizer Worldwide Research and Development / Michael DeRidder, Senior Director, Early pipeline commercial strategy, Oncology, Cell Therapy, GSK / Sir Gregory Winter, Master of Trintity Cambridge Universiry, Founder and co-Founder, Bicycle Therapeutics / Andre Choulika, CEO, Cellectis / Hans G. Klingemann, Vice President, Research and Development, NantKwest / John Delaney, Executive Director, Amgen Biologics Discovery / Andreas Plückthun